🍂 Enjoy the Fall Season! 🍂
MindTheDesk

Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug

Global - Asia Archived • November 12, 2026 • 3 views
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market.
China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed as Foundayo, could be used for chronic weight management by obese or overweight adults.
GLP-1 receptor agonists are synthetic...
Source: South China Morning Post | https://www.scmp.com/rss/91/feed - Read Original
"We build AI or anything ICST"
"House Plans for Structures New and Old"

Discussion (0)

Please log in to post a comment.

No comments yet. Be the first to share your thoughts!

Sponsored
"Retirement Health Care"
"Network Cable Repairs from $29"